Musculoskeletal Partnering Terms and Agreements

Introduction

The Musculoskeletal Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the musculoskeletal partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter musculoskeletal partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors musculoskeletal technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,500 links to online copies of actual musculoskeletal deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of musculoskeletal dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in musculoskeletal dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading musculoskeletal deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of musculoskeletal deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all musculoskeletal deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all musculoskeletal partnering deals signed and announced since 2007. The chapter is organized by specific musculoskeletal therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all musculoskeletal partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in musculoskeletal partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of musculoskeletal technologies and products.

Musculoskeletal Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of musculoskeletal deal trends since 2007
• Access musculoskeletal deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between musculoskeletal partner companies
• Comprehensive access to over 1,500 links to actual musculoskeletal deals entered into by the world's biopharma companies
• Indepth review of musculoskeletal deals entered into by the leading fifty bigpharma companies
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner musculoskeletal opportunities
• Uncover companies actively partnering musculoskeletal opportunities

Musculoskeletal Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to musculoskeletal trends and structure of deals entered into by leading companies worldwide.

Musculoskeletal Partnering Terms and Agreements includes:

• Trends in musculoskeletal dealmaking in the biopharma industry since 2007
• Analysis of musculoskeletal deal structure
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of musculoskeletal deal contract documents
• Comprehensive access to over 1,500 musculoskeletal deal records
• The leading musculoskeletal deals by value since 2007
• Most active musculoskeletal dealmakers since 2007

In Musculoskeletal Partnering Terms and Agreements, available deals and contracts are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Current Partnering was established in 2007 and has become the leading publisher of deal term reports within the life sciences. Designed to translate research into commercial success, Current Partnering provides an opportunity for the dissemination of the latest trends in partnering activity across the life sciences.

Current Partnering report titles cover all aspects of partnering best practice and deal terms, providing users with the information and insight required to optimise their partnering activities.

Current Partnering is a trademark of Wildwood Ventures Ltd..

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in musculoskeletal dealmaking

• 2.1. Introduction
• 2.2. Musculoskeletal partnering over the years
• 2.3. Bigpharma musculoskeletal dealmaking activity
• 2.4. Bigpharma not active in musculoskeletal
• 2.5. Musculoskeletal partnering by deal type
• 2.6. Musculoskeletal partnering by industry sector
• 2.7. Musculoskeletal partnering by stage of development
• 2.8. Musculoskeletal partnering by technology type
• 2.9. Musculoskeletal partnering by musculoskeletal indication
• 2.10. Average deal terms for musculoskeletal
• 2.10.1. Musculoskeletal headline values
• 2.10.2. Musculoskeletal upfront payments
• 2.10.3. Musculoskeletal milestone payments
• 2.10.4. Musculoskeletal royalty rates

Chapter 3 - Leading musculoskeletal deals

• 3.1. Introduction
• 3.2. Top musculoskeletal deals by value
• 3.3. Top musculoskeletal deals involving bigpharma

Chapter 4 - Bigpharma musculoskeletal deals

• 4.1. Introduction
• 4.2. How to use bigpharma partnering deals

• 4.3. Bigpharma musculoskeletal partnering company profiles
  • Abbott
  • Actavis
  • Amgen
  • Astellas
  • AstraZeneca
  • Biogen Idec
  • Bristol-Myers Squibb
  • Celgene
  • Daiichi Sankyo
  • Eisai
  • Eli Lilly
  • Endo Pharmaceuticals
  • Forest Laboratories
  • GlaxoSmithKline
  • Hospira
  • Johnson & Johnson
  • Menarini
  • Merck & Co
  • Merck KGaA
  • Novartis
  • Novo Nordisk
  • Otsuka
  • Pfizer
  • Roche
  • Sanofi
  • Servier
  • Shire
  • Takeda
  • UCB
  • Warner Chilcott

Chapter 5 - Musculoskeletal partnering contracts directory

• 5.1. Introduction

• 5.2. By deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Contract service
  • Co-promotion
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Grant
  • Licensing
  • Litigation
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Sub-license
  • Supply
  • Termination
  • Warranty

• 5.3. By stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

• 5.4. By technology type
  • Analysis
  • Assays
  • Biological compounds
  • Biomaterials
  • Cell therapy
  • Clinical testing
  • Devices
  • Diagnostics
  • Discovery tools
  • Drug delivery
  • Enabling technology
  • Equipment
  • Facilities
  • Gene therapy
  • Genomics
  • Implant
  • In vitro models
  • Natural product
  • Oligonucleotide
  • Packaging
  • Peptides
  • Processes
  • Proteomics
  • Radio/Chemo-therapy
  • Recombinant DNA
  • Regenerative medicine
  • Research services
  • Research supplies
  • RNA therapeutics
  • Screening
  • Small molecules
  • Stem cells
  • Vaccines

Chapter 6 - Musculoskeletal dealmaking by indication

• 6.1. Introduction

• 6.2. Deals by therapeutic indication
  • Musculoskeletal
  • Arthritis
  • Osteoarthritis
  • Psoriatic arthritis
  • Rheumatoid arthritis
  • Bone fracture
  • Hip
  • Gout
  • Knee
  • Muscular dystrophy
  • Back pain
  • Bone pain
  • Muscular pain
  • Stiffness
  • Osteoporosis
  • Paget's disease
  • Spinal muscular atrophy

Chapter 7 - Partnering resource center

• 7.1. Online partnering
• 7.2. Partnering events
• 7.3. Further reading on dealmaking

Appendices

• Appendix 1 - Directory of musculoskeletal deals by company A-Z 2007-2012
• Appendix 2 - Directory of musculoskeletal deals by deal type 2007-2012
• Appendix 3 - Directory of musculoskeletal deals by stage of development 2007-2012
• Appendix 4 - Directory of musculoskeletal deals by technology type 2007-2012
• Appendix 5 - Deal type definitions

• About Wildwood Ventures
• Current Partnering
• Current Agreements
• Recent titles from CurrentPartnering Order Form - Reports
• Order Form - Therapy Reports

• Figure 1: Musculoskeletal partnering since 2007
• Figure 2: Bigpharma - top 50 - musculoskeletal deals 2007 to 2012
• Figure 3: Bigpharma musculoskeletal deal frequency - 2007 to 2012
• Figure 4: Inactive bigpharma in musculoskeletal 2007-2012
• Figure 5: Musculoskeletal partnering by deal type since 2007
• Figure 6: Musculoskeletal partnering by industry sector since 2007
• Figure 7: Musculoskeletal partnering by stage of development since 2007
• Figure 8: Musculoskeletal partnering by technology type since 2007
• Figure 9: Musculoskeletal partnering by musculoskeletal target since 2007
• Figure 10: Musculoskeletal deals with a headline value
• Figure 11: Musculoskeletal deal headline value distribution, US$million - discovery stage
• Figure 12: Musculoskeletal deal headline value distribution, US$million - preclinical stage
• Figure 13: Musculoskeletal deal headline value distribution, US$million - phase I stage
• Figure 14: Musculoskeletal deal headline value distribution, US$million - phase II stage
• Figure 15: Musculoskeletal deal headline value distribution, US$million - phase III stage
• Figure 16: Musculoskeletal deal headline value distribution, US$million - regulatory stage
• Figure 17: Musculoskeletal deal headline value distribution, US$million - marketed stage
• Figure 18: Summary median headline value by stage of development, 2007-2012
• Figure 19 Musculoskeletal deals with upfront payment values
• Figure 20: Musculoskeletal deal upfront payment distribution, US$million - discovery stage
• Figure 21: Musculoskeletal deal upfront payment distribution, US$million - preclinical stage
• Figure 22: Musculoskeletal deal upfront payment distribution, US$million - phase I stage
• Figure 23: Musculoskeletal deal upfront payment distribution, US$million - phase II stage
• Figure 24: Musculoskeletal deal upfront payment distribution, US$million - phase III stage
• Figure 25: Musculoskeletal deal upfront payment distribution, US$million - regulatory stage
• Figure 26: Musculoskeletal deal upfront payment distribution, US$million - marketed stage
• Figure 27: Summary median upfront payments by stage of development, 2007-2012
• Figure 28: Musculoskeletal deals with milestone payments
• Figure 29: Musculoskeletal deal milestone distribution, US$million - discovery stage
• Figure 30: Musculoskeletal deal milestone distribution, US$million - preclinical stage
• Figure 31: Musculoskeletal deal milestone distribution, US$million - phase I stage
• Figure 32: Musculoskeletal deal milestone distribution, US$million - phase II stage
• Figure 33: Musculoskeletal deal milestone distribution, US$million - phase III stage
• Figure 34: Musculoskeletal deal milestone distribution, US$million - regulatory stage
• Figure 35: Musculoskeletal deal milestone distribution, US$million - marketed stage
• Figure 36: Musculoskeletal deals with royalty rates, %
• Figure 37: Musculoskeletal deal royalty rate distribution, US$million - discovery stage
• Figure 38: Musculoskeletal deal royalty rate distribution, US$million - preclinical stage
• Figure 39: Musculoskeletal deal royalty rate distribution, US$million - phase I stage
• Figure 40: Musculoskeletal deal royalty rate distribution, US$million - phase II stage
• Figure 41: Musculoskeletal deal royalty rate distribution, US$million - phase III stage
• Figure 42: Musculoskeletal deal royalty rate distribution, US$million - regulatory stage
• Figure 44: Summary median royalty rate by stage of development, 2007-2012
• Figure 45: Top musculoskeletal deals by value since 2007
• Figure 46: Top musculoskeletal deals signed by bigpharma value since 2007
• Figure 47: Online partnering resources
• Figure 48: Forthcoming partnering events

Musculoskeletal Partnering Terms and Agreements published by Current Partnering, a division of Wildwood Ventures Limited. This report consists of 1009 Pages and the price starts from US $ 2695.

The contents of this page may be different from the latest version. Please contact us for details.